Depressive Disorder, Treatment-Resistant
"Depressive Disorder, Treatment-Resistant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Failure to respond to two or more trials of antidepressant monotherapy or failure to respond to four or more trials of different antidepressant therapies. (Campbell's Psychiatric Dictionary, 9th ed.)
| Descriptor ID |
D061218
|
| MeSH Number(s) |
F03.600.300.388
|
| Concept/Terms |
Depressive Disorder, Treatment-Resistant- Depressive Disorder, Treatment-Resistant
- Depressive Disorder, Treatment Resistant
- Depressive Disorders, Treatment-Resistant
- Disorder, Treatment-Resistant Depressive
- Disorders, Treatment-Resistant Depressive
- Treatment-Resistant Depressive Disorder
- Treatment-Resistant Depressive Disorders
- Refractory Depression
- Depression, Refractory
- Depressions, Refractory
- Refractory Depressions
- Therapy-Resistant Depression
- Depression, Therapy-Resistant
- Depressions, Therapy-Resistant
- Therapy Resistant Depression
- Therapy-Resistant Depressions
- Treatment Resistant Depression
- Depression, Treatment Resistant
- Depressions, Treatment Resistant
- Resistant Depression, Treatment
- Resistant Depressions, Treatment
- Treatment Resistant Depressions
|
Below are MeSH descriptors whose meaning is more general than "Depressive Disorder, Treatment-Resistant".
Below are MeSH descriptors whose meaning is more specific than "Depressive Disorder, Treatment-Resistant".
This graph shows the total number of publications written about "Depressive Disorder, Treatment-Resistant" by people in this website by year, and whether "Depressive Disorder, Treatment-Resistant" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 4 | 0 | 4 |
| 2015 | 4 | 0 | 4 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 1 | 3 |
| 2018 | 5 | 0 | 5 |
| 2019 | 5 | 0 | 5 |
| 2020 | 3 | 2 | 5 |
| 2021 | 6 | 0 | 6 |
| 2022 | 5 | 0 | 5 |
| 2023 | 7 | 0 | 7 |
| 2024 | 8 | 3 | 11 |
| 2025 | 7 | 1 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Depressive Disorder, Treatment-Resistant" by people in Profiles.
-
Comparing the Cognitive Effects of Repeated Intravenous Ketamine and Electroconvulsive Therapy in Patients With Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial. J Clin Psychiatry. 2025 Sep 03; 86(4).
-
Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD). J Affect Disord. 2025 Dec 01; 390:119836.
-
Comparing the effects of ECT and intravenous ketamine in psychiatric patients with major depressive episodes. J Affect Disord. 2025 Nov 15; 389:119727.
-
Safety and efficacy of Deep TMS for adolescent depression based on large real-world data analysis. Psychiatry Res. 2025 Aug; 350:116567.
-
Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov. Psychiatry Res. 2025 Aug; 350:116559.
-
Regulatory Alignment of Psilocybin Clinical Trials in Major Depressive Disorder on ClinicalTrials.gov: A Cross-Sectional Analysis. Pharmacopsychiatry. 2025 Jul; 58(4):187-197.
-
Lack of relationships between ketamine treatment and peripheral neurotrophic and inflammatory factors in a randomized controlled ketamine trial of major depressive disorder. Brain Behav Immun. 2025 Aug; 128:170-178.
-
Patient preference effects in a randomized comparative effectiveness study of electroconvulsive therapy and ketamine for treatment resistant depression: An ELEKT-D trial secondary analysis. Psychiatry Res. 2025 May; 347:116411.
-
Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials. Psychiatry Res. 2025 Feb; 344:116337.
-
Difficult to Treat Depression: Focus on Approach, Algorithms, and Access. J Clin Psychiatry. 2024 Nov 25; 85(4).